Smart drug development for better patient treatment and value creation

Clinical trials

Debiopharm’s vision of healthcare is not limited to making new medicines available. We strongly believe you can be an actor in your own medical care.

More about clinical trials
Debiopharm Innovation Fund

Debiopharm Innovation Fund’s portfolio company BC Platforms to create a Health Data Discovery Platform for…

Read more
Debiopharm Group

Grand succès du 3e Challenge pour la Qualité de vie des patients

Read more

GenePOC® launches its GenePOC® CDiff test in Canada

Read more
Your task is not to foresee the future, but to enable it.
Antoine de St-Exupéry


For more than 35 years, we have been passionate about what we do: drug development.

Our story began in 1979 when Dr Rolland-Yves Mauvernay, convinced that many useful therapeutic products were abandoned before reaching their full potential, decided to found the Swiss-based Debiopharm Group. Having started with only two people, Debiopharm is now a group of five companies active in the life science areas of drug development, GMP manufacturing of proprietary drugs, diagnostic tools and investment management. Together with his son Thierry Mauvernay, they have built a team of well over 420 dedicated professionals.

The Group is now headed up by Mr Thierry Mauvernay, driven by the same passion as his father. He is fully committed to the group’s current activities and planning the future to ensure long-term continuity.


Be part of the Debiopharm's team


Medical Director, Clinical Pharmacology

More info

Associate Director, Global Regulatory Affairs

More info
Work at Debiopharm
Social responsibility

We are dedicated to contributing positively to the development and wellbeing of projects we believe in.

Learn more
Media Library

Find contact for media inquiries & download corporate resources

Awards and Grants

Each year Debiopharm co-organizes and presents two honors: the JCA-Mauvernay Award and the "Challenge Debiopharm-Inartis" Grant

Press releases

Discover the latest media announcements about Debiopharm Group and its companies